ESR1 and neoplasm: Treatments that target the ER include blocking of receptor with an antagonist (e.g., selective estrogen receptor modulators such as tamoxifen or selective estrogen receptor disruptors such as fulvestrant), or depriving the tumor of estrogen (aromatase inhibitors).